{"pmid":32314322,"title":"COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights.","text":["COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights.","Int Ophthalmol","Neri, Piergiorgio","Pichi, Francesco","32314322"],"journal":"Int Ophthalmol","authors":["Neri, Piergiorgio","Pichi, Francesco"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314322","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s10792-020-01389-2","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664714520110563330,"score":8.518259,"similar":[{"pmid":32022370,"pmcid":"PMC7162020","title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","text":["Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.","Chembiochem","Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray","32022370"],"abstract":["With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics."],"journal":"Chembiochem","authors":["Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32022370","week":"20206|Feb 03 - Feb 09","doi":"10.1002/cbic.202000047","keywords":["2019-ncov","3clpro","rdrp","sars","antiviral agents","coronavirus","spike proteins"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["remdesivir"],"_version_":1664640875372740610,"score":78.718575},{"pmid":32269357,"title":"COVID-19 in humanitarian settings and lessons learned from past epidemics.","text":["COVID-19 in humanitarian settings and lessons learned from past epidemics.","Nat Med","Lau, Ling San","Samari, Goleen","Moresky, Rachel T","Casey, Sara E","Kachur, S Patrick","Roberts, Leslie F","Zard, Monette","32269357"],"journal":"Nat Med","authors":["Lau, Ling San","Samari, Goleen","Moresky, Rachel T","Casey, Sara E","Kachur, S Patrick","Roberts, Leslie F","Zard, Monette"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32269357","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41591-020-0851-2","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664637315659595776,"score":75.07402},{"pmid":32222113,"title":"Learning from history: Coronavirus outbreaks in the past.","text":["Learning from history: Coronavirus outbreaks in the past.","Dermatol Ther","Arora, Pooja","Jafferany, Mohammad","Lotti, Torello","Sadoughifar, Roxanna","Goldust, Mohamad","32222113"],"journal":"Dermatol Ther","authors":["Arora, Pooja","Jafferany, Mohammad","Lotti, Torello","Sadoughifar, Roxanna","Goldust, Mohamad"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32222113","week":"202014|Mar 30 - Apr 05","doi":"10.1111/dth.13343","source":"PubMed","topics":["Mechanism","Transmission"],"weight":1,"_version_":1664638629695193088,"score":65.066666},{"pmid":32047315,"title":"Coronavirus: hospitals must learn from past pandemics.","text":["Coronavirus: hospitals must learn from past pandemics.","Nature","Bhadelia, Nahid","32047315"],"journal":"Nature","authors":["Bhadelia, Nahid"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32047315","week":"20207|Feb 10 - Feb 16","doi":"10.1038/d41586-020-00354-4","keywords":["health care","infection","virology"],"link_comment_for":"23838223","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664640875319263234,"score":65.066666},{"pmid":32143502,"title":"Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.","text":["Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.","Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. The continuous evolution of coronaviruses was further highlighted with the emergence of the Middle East Respiratory Syndrome-CoV (MERS-CoV) outbreak in 2012. Currently, the world is concerned about the 2019 novel CoV (SARS-CoV-2) that was initially identified in the city of Wuhan, China in December 2019. Patients presented with severe viral pneumonia and respiratory illness. The number of cases has been mounting since then. As of late February 2020, tens of thousands of cases and several thousand deaths have been reported in China alone, in addition to thousands of cases in other countries. Although the fatality rate of SARS-CoV-2 is currently lower than SARS-CoV, the virus seems to be highly contagious based on the number of infected cases to date. In this review, we discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks. The future of human CoV outbreaks will not only depend on how the viruses will evolve, but will also depend on how we develop efficient prevention and treatment strategies to deal with this continuous threat.","Pathogens","Ashour, Hossam M","Elkhatib, Walid F","Rahman, Md Masudur","Elshabrawy, Hatem A","32143502"],"abstract":["Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. The continuous evolution of coronaviruses was further highlighted with the emergence of the Middle East Respiratory Syndrome-CoV (MERS-CoV) outbreak in 2012. Currently, the world is concerned about the 2019 novel CoV (SARS-CoV-2) that was initially identified in the city of Wuhan, China in December 2019. Patients presented with severe viral pneumonia and respiratory illness. The number of cases has been mounting since then. As of late February 2020, tens of thousands of cases and several thousand deaths have been reported in China alone, in addition to thousands of cases in other countries. Although the fatality rate of SARS-CoV-2 is currently lower than SARS-CoV, the virus seems to be highly contagious based on the number of infected cases to date. In this review, we discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks. The future of human CoV outbreaks will not only depend on how the viruses will evolve, but will also depend on how we develop efficient prevention and treatment strategies to deal with this continuous threat."],"journal":"Pathogens","authors":["Ashour, Hossam M","Elkhatib, Walid F","Rahman, Md Masudur","Elshabrawy, Hatem A"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32143502","week":"202010|Mar 02 - Mar 08","doi":"10.3390/pathogens9030186","keywords":["2019-ncov","covid-19","mers","sars","sars-cov-2"],"source":"PubMed","topics":["Mechanism","Prevention","Treatment"],"weight":1,"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874915561472,"score":63.632515}]}